Mean platelet volume as diagnostic and therapeutic marker of risk and prognosis of heart disease

Submitted: 20 August 2017
Accepted: 15 December 2017
Published: 11 January 2018
Abstract Views: 1563
PDF: 695
HTML: 619
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Increased mean platelet volume (MPV) is associated with platelet reactivity and is a predictor of cardiovascular risk and unprovoked nervous thromboembolism. Mean platelet volume is a precise measure of platelet size. Studies have reported the use of MPV as a biomarker for predicting ischemic stroke in atrial fibrillation patients as well as in anticoagulant prescription and rhythm-control therapy. Moreover, MPV may predict cardiovascular event outcome following percutaneous coronary intervention in patients with coronary artery disease. MPV may predict residual platelet reactivity in dual antiplatelet therapy. Factors influencing MPV result were discussed. This review centered on the reports that MPV may be a biomarker of risk and prognosis of prevalent heart diseases.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Henshaw Uchechi Okoroiwu, Hematology Unit, Department of Medical Laboratory Science, University of Calabar
Haematologist (MSc, PhD in view)

How to Cite

Okoroiwu, H. U., & Ogar, C. O. (2018). Mean platelet volume as diagnostic and therapeutic marker of risk and prognosis of heart disease. Italian Journal of Medicine, 12(1), 10–14. https://doi.org/10.4081/itjm.2018.918